In addition, anti-HER2 monoclonal antibodies are known to mainly exert their action by activating the immune system through the mechanism of antibody-dependent cell mediated cytotoxicity (ADCC), thus enhancing the immunogenicity of this BC subtype [9, 10]. The gene discussed is ERBB2; the disease is breast cancer.